SG11201804178YA - Pd1 and/or lag3 binders - Google Patents
Pd1 and/or lag3 bindersInfo
- Publication number
- SG11201804178YA SG11201804178YA SG11201804178YA SG11201804178YA SG11201804178YA SG 11201804178Y A SG11201804178Y A SG 11201804178YA SG 11201804178Y A SG11201804178Y A SG 11201804178YA SG 11201804178Y A SG11201804178Y A SG 11201804178YA SG 11201804178Y A SG11201804178Y A SG 11201804178YA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- rule
- technologiepark
- california
- avenue
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau IIII1111111111111111111111111111111111111111111111111111111H111111111R111111111111111 (10) International Publication Number WO 2017/087589 A2 WIPO I PCT (43) International Publication Date 26 May 2017 (26.05.2017) (51) International Patent Classification: BOUTTON, Carlo [BE/BE]; Technologiepark 21, 9052 C07K 16/28 (2006.01) C07K 16/18 (2006.01) Zwijnaarde (BE). (21) International Application Number: (72) Inventors; and PCT/US2016/062394 (71) Applicants (for NZ, US only): DOMBRECHT, Bruno (22) International Filing Date: 17 November 2016 (17.11.2016) VLERICK, David [BE/BE]; Technologiepark 21, 9052 Zwijnaarde (BE). [BE/BE]; Technologiepark 21, 9052 Zwijnaaarde (BE). (25) Filing Language: English (74) Common Representative: MERCK SHARP & DOHME CORP.; 126 East Lincoln Avenue, Rahway, New Jersey (26) Publication Language: English 07065-0907 (US). (30) Priority Data: (81) Designated States (unless otherwise indicated, for every 62/257,009 18 November 2015 (18.11.2015) US kind of national protection available): AE, AG, AL, AM, (71) Applicant (for all designated States except US): MERCK AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, SHARP & DOHME CORP. [US/US]; 126 East Lincoln BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, Avenue, Rahway, New Jersey 07065-0907 (US). DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (72) Inventors; and KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (71) Applicants (for NZ, US only): BOWMAN, Edward MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, [US/US]; 901 S. California Avenue, Palo Alto, California OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, 94304 (US). BEAUMONT, Maribel [FR/US]; 901 S. SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, California Avenue, Palo Alto, California 94304 (US). TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (72) Inventors; and ZW. (71) Applicants (for US only): BUYSE, Marie-Ange [BE/BE]; Technologiepark 21, 9052 Zwijnaarde (BE). [Continued on next page] (54) Title: PD1 AND/OR LAG3 BINDERS Cancer Patient Sera • • • 350 300 co - tp 0 250 co 200 CNI 150 100 W O 20 17 /0875 89 A2 • • 1013700112 F023700924 F023700931 FIG.19C (57) : The present invention provides molecules, such as ISVDs and Nanobodies, that bind to PD1 and LAG3 and, option- ally to human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing anti - bodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided. WO 2017/087589 A2MIDEDIM0111 DIOIRDIDEM11111111111111111111111111111111111111111111111111111 (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: without international search report and to be republished upon receipt of that report (Rule 48.2(g)) with sequence listing part of description (Rule 5.2(a))
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562257009P | 2015-11-18 | 2015-11-18 | |
PCT/US2016/062394 WO2017087589A2 (en) | 2015-11-18 | 2016-11-17 | Pd1 and/or lag3 binders |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201804178YA true SG11201804178YA (en) | 2018-06-28 |
Family
ID=57472067
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201804178YA SG11201804178YA (en) | 2015-11-18 | 2016-11-17 | Pd1 and/or lag3 binders |
SG10201911035QA SG10201911035QA (en) | 2015-11-18 | 2016-11-17 | Pd1 and/or lag3 binders |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201911035QA SG10201911035QA (en) | 2015-11-18 | 2016-11-17 | Pd1 and/or lag3 binders |
Country Status (31)
Country | Link |
---|---|
US (5) | US10323090B2 (en) |
EP (1) | EP3377531A2 (en) |
JP (3) | JP6817302B2 (en) |
KR (3) | KR102194188B1 (en) |
CN (1) | CN108473585B (en) |
AR (1) | AR106754A1 (en) |
AU (3) | AU2016355570B2 (en) |
BR (1) | BR112018010084A2 (en) |
CA (3) | CA3132021C (en) |
CL (3) | CL2018001327A1 (en) |
CO (1) | CO2018005126A2 (en) |
CR (1) | CR20180278A (en) |
DO (2) | DOP2018000126A (en) |
EA (1) | EA201891165A1 (en) |
EC (1) | ECSP18045468A (en) |
GE (1) | GEP20217220B (en) |
HK (1) | HK1254951A1 (en) |
IL (2) | IL300122A (en) |
JO (1) | JO3744B1 (en) |
MA (1) | MA43260A (en) |
MX (2) | MX2018006245A (en) |
MY (1) | MY189018A (en) |
NI (1) | NI201800061A (en) |
PE (1) | PE20181532A1 (en) |
PH (1) | PH12018501080A1 (en) |
SG (2) | SG11201804178YA (en) |
SV (1) | SV2018005694A (en) |
TN (1) | TN2018000172A1 (en) |
TW (2) | TW202216787A (en) |
UA (1) | UA121914C2 (en) |
WO (1) | WO2017087589A2 (en) |
Families Citing this family (87)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2437327T3 (en) | 2007-06-18 | 2014-01-10 | Merck Sharp & Dohme B.V. | Antibodies for the human programmed PD-1 receptor of programmed death |
US11644471B2 (en) | 2010-09-30 | 2023-05-09 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
KR20220114104A (en) | 2011-06-23 | 2022-08-17 | 아블린쓰 엔.브이. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
CN109053885A (en) | 2014-05-16 | 2018-12-21 | 埃博灵克斯股份有限公司 | Improved immunoglobulin variable domain domain |
KR20180040138A (en) | 2015-07-13 | 2018-04-19 | 싸이톰스 테라퓨틱스, 인크. | Anti-PD-1 antibodies, activatable anti-PD-1 antibodies, and methods of using them |
TWI756187B (en) | 2015-10-09 | 2022-03-01 | 美商再生元醫藥公司 | Anti-lag3 antibodies and uses thereof |
CN114605530A (en) * | 2015-11-18 | 2022-06-10 | 埃博灵克斯股份有限公司 | Improved serum albumin binders |
SG11201804178YA (en) * | 2015-11-18 | 2018-06-28 | Merck Sharp & Dohme | Pd1 and/or lag3 binders |
UA125337C2 (en) | 2015-11-18 | 2022-02-23 | Мерк Шарп І Доум Корп. | Ctla4 binders |
ES2858091T3 (en) | 2016-06-20 | 2021-09-29 | F Star Therapeutics Ltd | Binding molecules that bind to PD-L1 and LAG-3 |
RU2769282C2 (en) | 2016-06-20 | 2022-03-30 | Кимаб Лимитед | Anti-pd-l1 and il-2 cytokines |
AU2017281157A1 (en) | 2016-06-20 | 2019-01-31 | F-Star Therapeutics Limited | LAG -3 binding members |
GB201612520D0 (en) | 2016-07-19 | 2016-08-31 | F-Star Beta Ltd | Binding molecules |
TW202246349A (en) | 2016-10-11 | 2022-12-01 | 美商艾吉納斯公司 | Anti-lag-3 antibodies and methods of use thereof |
EP3565842A1 (en) | 2017-01-06 | 2019-11-13 | Crescendo Biologics Limited | Single domain antibodies to programmed cell death (pd-1) |
SG11201907208XA (en) | 2017-02-10 | 2019-09-27 | Regeneron Pharma | Radiolabeled anti-lag3 antibodies for immuno-pet imaging |
WO2018217940A2 (en) * | 2017-05-24 | 2018-11-29 | Sutro Biopharma, Inc. | Pd-1/lag3 bi-specific antibodies, compositions thereof, and methods of making and using the same |
EP3630842A2 (en) | 2017-05-30 | 2020-04-08 | Bristol-Myers Squibb Company | Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent |
US11723975B2 (en) | 2017-05-30 | 2023-08-15 | Bristol-Myers Squibb Company | Compositions comprising an anti-LAG-3 antibody or an anti-LAG-3 antibody and an anti-PD-1 or anti-PD-L1 antibody |
CN110720039A (en) | 2017-05-30 | 2020-01-21 | 百时美施贵宝公司 | Treatment of LAG-3 positive tumors |
WO2019009728A1 (en) * | 2017-07-06 | 2019-01-10 | Merus N.V. | Antibodies that modulate a biological activity expressed by a cell |
SG11202004426SA (en) * | 2017-11-17 | 2020-06-29 | Merck Sharp & Dohme | Antibodies specific for immunoglobulin-like transcript 3 (ilt3) and uses thereof |
US11548948B2 (en) | 2017-12-19 | 2023-01-10 | F-Star Therapeutics Limited | FC binding fragments comprising a PD-L1 antigen-binding site |
KR20200104886A (en) * | 2017-12-28 | 2020-09-04 | 난징 레전드 바이오테크 씨오., 엘티디. | Antibodies and variants against PD-L1 |
WO2019137541A1 (en) * | 2018-01-15 | 2019-07-18 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against pd-1 |
US11655295B2 (en) | 2018-01-18 | 2023-05-23 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Anti-LAG-3 antibody and use thereof |
WO2019149716A1 (en) * | 2018-01-31 | 2019-08-08 | F. Hoffmann-La Roche Ag | Bispecific antibodies comprising an antigen-binding site binding to lag3 |
WO2019148412A1 (en) * | 2018-02-01 | 2019-08-08 | Merck Sharp & Dohme Corp. | Anti-pd-1/lag3 bispecific antibodies |
GB201802573D0 (en) * | 2018-02-16 | 2018-04-04 | Crescendo Biologics Ltd | Therapeutic molecules that bind to LAG3 |
JP7438180B2 (en) * | 2018-03-20 | 2024-02-26 | ウーシー バイオロジクス アイルランド リミテッド | Novel anti-LAG-3 antibody polypeptide |
CN112236456B (en) * | 2018-03-20 | 2023-12-22 | 上海药明生物技术有限公司 | Novel bispecific PD-1/LAG-3 antibody molecules |
US20210061912A1 (en) * | 2018-03-20 | 2021-03-04 | WuXi Biologics Ireland Limited | Novel anti-pd-1 antibodies |
CN111886254B (en) * | 2018-03-30 | 2023-12-08 | 南京传奇生物科技有限公司 | Single domain antibodies against LAG-3 and uses thereof |
KR20210005894A (en) * | 2018-05-03 | 2021-01-15 | 상하이 에피맙 바이오테라퓨틱스 컴퍼니, 리미티드 | High affinity antibodies to PD-1 and LAG-3 and bispecific binding proteins prepared therefrom |
US11136394B2 (en) | 2018-05-17 | 2021-10-05 | Nanjing Leads Biolabs Co., Ltd. | Antibody binding PD-1 and use thereof |
SG11202100693UA (en) | 2018-07-26 | 2021-02-25 | Bristol Myers Squibb Co | Lag-3 combination therapy for the treatment of cancer |
CN113164616A (en) | 2018-09-26 | 2021-07-23 | 阿森迪斯药物股份有限公司 | Degradable hyaluronic acid hydrogel |
CA3117016A1 (en) | 2018-10-19 | 2020-04-23 | Bristol-Myers Squibb Company | Combination therapy for melanoma |
US20230051872A1 (en) * | 2019-03-22 | 2023-02-16 | Reflexion Pharmaceuticals, Inc. | Multivalent D-Peptidic Compounds for Target Proteins |
EP3715375A1 (en) | 2019-03-23 | 2020-09-30 | Ablevia biotech GmbH | Compound for the prevention or treatment of pre-eclampsia |
EP3715376A1 (en) | 2019-03-23 | 2020-09-30 | Ablevia biotech GmbH | Compound for the prevention or treatment of myasthenia gravis |
EP3715374A1 (en) | 2019-03-23 | 2020-09-30 | Ablevia biotech GmbH | Compound for the sequestration of undesirable antibodies in a patient |
SG11202111441QA (en) * | 2019-04-26 | 2021-11-29 | Wuxi Biologics Ireland Ltd | Bispecific antibodies against pd-1 and lag-3 |
CN110179977A (en) * | 2019-05-22 | 2019-08-30 | 华中科技大学同济医学院附属同济医院 | For treating melanoma, lung cancer or the combined pharmaceutical formulation of colorectal cancer |
KR20220016157A (en) | 2019-05-30 | 2022-02-08 | 브리스톨-마이어스 스큅 컴퍼니 | Cell localization signatures and combination therapies |
CN114127315A (en) | 2019-05-30 | 2022-03-01 | 百时美施贵宝公司 | Method of identifying subjects suitable for immunooncology (I-O) therapy |
JP2022534967A (en) | 2019-05-30 | 2022-08-04 | ブリストル-マイヤーズ スクイブ カンパニー | Multiple tumor gene signatures and their uses |
WO2020263717A1 (en) * | 2019-06-26 | 2020-12-30 | Merck Sharp & Dohme Corp. | Process for separating antigen-binding polypeptide monomers comprising one or more immunoglobulin single variable domains from aggregates |
WO2021008559A1 (en) * | 2019-07-16 | 2021-01-21 | Wuxi Biologics (Shanghai) Co., Ltd. | Bispecific antibodies against pd-1 and lag-3 |
WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
CN110981958B (en) * | 2019-08-23 | 2020-10-20 | 四川大学华西医院 | PD-L1 antibody |
KR20220066334A (en) | 2019-09-22 | 2022-05-24 | 브리스톨-마이어스 스큅 컴퍼니 | Quantitative spatial profiling for LAG-3 antagonist therapy |
CN112739721B (en) * | 2019-09-26 | 2023-01-31 | 苏州克睿基因生物科技有限公司 | Single-domain antibody and chimeric antigen receptor containing antibody structure |
WO2021092220A1 (en) | 2019-11-06 | 2021-05-14 | Bristol-Myers Squibb Company | Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy |
WO2021092221A1 (en) | 2019-11-06 | 2021-05-14 | Bristol-Myers Squibb Company | Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy |
JP2022553851A (en) | 2019-11-08 | 2022-12-26 | ブリストル-マイヤーズ スクイブ カンパニー | LAG-3 antagonists for the treatment of melanoma |
WO2021158938A1 (en) | 2020-02-06 | 2021-08-12 | Bristol-Myers Squibb Company | Il-10 and uses thereof |
EP4178611A1 (en) | 2020-07-07 | 2023-05-17 | BioNTech SE | Therapeutic rna for hpv-positive cancer |
EP4204095A1 (en) | 2020-08-28 | 2023-07-05 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for hepatocellular carcinoma |
AU2021334361A1 (en) | 2020-08-31 | 2023-05-11 | Bristol-Myers Squibb Company | Cell localization signature and immunotherapy |
WO2022063879A1 (en) | 2020-09-23 | 2022-03-31 | Ablevia Biotech Gmbh | Compound for the sequestration of undesirable antibodies in a patient |
EP4232019A1 (en) | 2020-10-23 | 2023-08-30 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for lung cancer |
WO2022109987A1 (en) * | 2020-11-27 | 2022-06-02 | Shanghai Benemae Pharmaceutical Corporation | Novel anti-lag3 antibodies and methods of making and using the same |
WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
TW202245808A (en) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | Therapeutic rna for treating cancer |
US20220233689A1 (en) | 2020-12-28 | 2022-07-28 | Bristol-Myers Squibb Company | Methods of treating tumors |
US20220233693A1 (en) | 2020-12-28 | 2022-07-28 | Bristol-Myers Squibb Company | Antibody Compositions and Methods of Use Thereof |
CN117858719A (en) | 2021-03-29 | 2024-04-09 | 朱诺治疗学股份有限公司 | Methods of dosing and treatment using a combination of checkpoint inhibitor therapy and CAR T cell therapy |
WO2022240741A1 (en) | 2021-05-12 | 2022-11-17 | Dana-Farber Cancer Institute, Inc. | Lag3 and gal3 inhibitory agents, xbp1, cs1, and cd138 peptides, and methods of use thereof |
CN113307874B (en) * | 2021-05-31 | 2022-05-27 | 广州爱思迈生物医药科技有限公司 | anti-LAG3antibody and application thereof |
WO2022266235A1 (en) * | 2021-06-15 | 2022-12-22 | The Trustees Of Columbia University In The City Of New York | Nanobodies against sars-cov-2 for detection of sars-cov-2, and diagnosis, treatment and prevention of infection and disease caused by sars-cov-2 |
AU2022312698A1 (en) | 2021-07-13 | 2024-01-25 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer |
CA3227334A1 (en) | 2021-07-28 | 2023-02-02 | Tiumbio Co., Ltd. | Pharmaceutical composition for preventing or treating tumor, and use thereof |
TW202333802A (en) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | Therapeutic rna for lung cancer |
IL309227A (en) | 2021-10-29 | 2024-02-01 | Bristol Myers Squibb Co | Lag-3 antagonist therapy for hematological cancer |
WO2023147371A1 (en) | 2022-01-26 | 2023-08-03 | Bristol-Myers Squibb Company | Combination therapy for hepatocellular carcinoma |
WO2023164638A1 (en) | 2022-02-25 | 2023-08-31 | Bristol-Myers Squibb Company | Combination therapy for colorectal carcinoma |
WO2023168404A1 (en) | 2022-03-04 | 2023-09-07 | Bristol-Myers Squibb Company | Methods of treating a tumor |
WO2023170606A1 (en) | 2022-03-08 | 2023-09-14 | Alentis Therapeutics Ag | Use of anti-claudin-1 antibodies to increase t cell availability |
WO2023178329A1 (en) | 2022-03-18 | 2023-09-21 | Bristol-Myers Squibb Company | Methods of isolating polypeptides |
CN115028726B (en) * | 2022-03-31 | 2024-01-09 | 浙江特瑞思药业股份有限公司 | anti-PD-1 nano antibody and application thereof |
CN114984207B (en) * | 2022-05-09 | 2024-01-26 | 浙江特瑞思药业股份有限公司 | anti-PD-1 nano antibody preparation |
WO2023235847A1 (en) | 2022-06-02 | 2023-12-07 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
WO2024017281A1 (en) * | 2022-07-20 | 2024-01-25 | 明慧医药(杭州)有限公司 | Multispecific antibody and use thereof |
US20240101718A1 (en) * | 2022-09-28 | 2024-03-28 | Incyte Corporation | Anti-pd-1/lag-3 bispecific antibodies and uses thereof |
Family Cites Families (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2532858B2 (en) | 1985-04-01 | 1996-09-11 | セルテツク リミテツド | Transformed myeloma cell line |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US5397703A (en) | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
EP1621554B2 (en) | 1992-08-21 | 2012-08-29 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
JPH08502168A (en) | 1992-09-29 | 1996-03-12 | プレジデント・アンド・フエローズ・オブ・ハーバード・カレツジ | Trophic factors with ion channel-inducing activity in neuronal cells |
US6824779B1 (en) | 1993-07-26 | 2004-11-30 | Dana-Farber Cancer Institute, Inc. | Methods for inhibiting the interaction of B7-2 with its natural ligand |
EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
DK1027439T3 (en) | 1997-10-27 | 2010-05-10 | Bac Ip Bv | Multivalent antigen-binding proteins |
ES2420835T3 (en) | 1999-04-09 | 2013-08-27 | Kyowa Hakko Kirin Co., Ltd. | Procedure to control the activity of immunofunctional molecules |
US20020006403A1 (en) | 1999-12-14 | 2002-01-17 | Xue-Zhong Yu | CD28-specific antibody compositions for use in methods of immunosuppression |
US7795002B2 (en) | 2000-06-28 | 2010-09-14 | Glycofi, Inc. | Production of galactosylated glycoproteins in lower eukaryotes |
WO2002026265A2 (en) | 2000-09-29 | 2002-04-04 | Schering Corporation | Pegylated interleukin-10 |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
US7723482B2 (en) | 2000-12-26 | 2010-05-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Anti-CD28 antibody |
AR036993A1 (en) | 2001-04-02 | 2004-10-20 | Wyeth Corp | USE OF AGENTS THAT MODULATE THE INTERACTION BETWEEN PD-1 AND ITS LINKS IN THE SUBMODULATION OF IMMUNOLOGICAL ANSWERS |
EP1456652A4 (en) | 2001-11-13 | 2005-11-02 | Dana Farber Cancer Inst Inc | Agents that modulate immune cell activation and methods of use thereof |
US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
EP1565877A1 (en) | 2002-10-24 | 2005-08-24 | Duke University | Binary prediction tree modeling with many predictors |
CA2505325C (en) | 2002-11-08 | 2014-02-25 | Ablynx N.V. | Stabilized single domain antibodies |
DK1687338T3 (en) | 2003-11-07 | 2011-02-07 | Ablynx Nv | Camelidae single-domain antibodies VHH targeting epidermal growth factor receptor and uses thereof |
PE20090047A1 (en) | 2003-11-10 | 2009-01-26 | Schering Corp | RECOMBINANT ANTI-INTERLEUQUIN HUMANIZED ANTIBODY 10 |
WO2006040153A2 (en) | 2004-10-13 | 2006-04-20 | Ablynx N.V. | Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease |
GB0521621D0 (en) | 2005-10-24 | 2005-11-30 | Domantis Ltd | Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases |
SG184709A1 (en) | 2005-05-18 | 2012-10-30 | Ablynx Nv | Improved nanobodies™ against tumor necrosis factor-alpha |
DK1907424T3 (en) | 2005-07-01 | 2015-11-09 | Squibb & Sons Llc | HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED death ligand 1 (PD-L1) |
JP2010500876A (en) | 2006-08-18 | 2010-01-14 | アブリンクス エン.ヴェー. | Amino acid sequence directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6 mediated signaling |
AU2007328900A1 (en) | 2006-12-05 | 2008-06-12 | Ablynx N.V. | Peptides capable of binding to serum proteins |
US8907065B2 (en) | 2006-12-15 | 2014-12-09 | Ablynx N.V. | Polypeptides that modulate the interaction between cells of the immune system |
WO2008132516A1 (en) | 2007-04-26 | 2008-11-06 | Opsona Therapeutics Limited | Toll-like receptor binding epitope and compositions for binding thereto |
CN101796072B (en) | 2007-05-24 | 2014-09-24 | 埃博灵克斯股份有限公司 | Amino acid sequences directed against RANK-l and polypeptides comprising the same for the treatment of bone diseases and disorders |
AU2008328785A1 (en) | 2007-11-27 | 2009-06-04 | Ablynx N.V. | Method for obtaining polypeptide constructs comprising two or more single domain antibodies |
NZ589036A (en) | 2008-05-16 | 2012-07-27 | Ablynx Nv | AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME |
WO2010007376A2 (en) * | 2008-07-18 | 2010-01-21 | Domantis Limited | Compositions monovalent for cd28 binding and methods of use |
AR072999A1 (en) | 2008-08-11 | 2010-10-06 | Medarex Inc | HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE |
US20110223188A1 (en) | 2008-08-25 | 2011-09-15 | Solomon Langermann | Targeted costimulatory polypeptides and methods of use to treat cancer |
KR20120038494A (en) | 2009-07-16 | 2012-04-23 | 글락소 그룹 리미티드 | Improved anti-serum albumin binding single variable domains |
AU2011275749C1 (en) | 2010-07-09 | 2015-09-17 | Aduro Biotech Holdings, Europe B.V. | Agonistic antibody to CD27 |
CN103917560B (en) | 2011-03-28 | 2017-05-24 | 埃博灵克斯股份有限公司 | Bispecific anti-CXCR7 immunoglobulin single variable domains |
US10076245B2 (en) | 2011-06-22 | 2018-09-18 | Canon Kabushiki Kaisha | Specimen information acquisition apparatus and specimen information acquisition method |
KR20220114104A (en) | 2011-06-23 | 2022-08-17 | 아블린쓰 엔.브이. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
HUE047238T2 (en) | 2011-06-23 | 2020-04-28 | Ablynx Nv | Serum albumin binding proteins |
CA2845029A1 (en) | 2011-08-17 | 2013-02-21 | Glaxo Group Limited | Modified proteins and peptides |
WO2013066765A1 (en) | 2011-11-01 | 2013-05-10 | Merck Sharp & Dohme Corp. | Mutation of tup1 in glycoengineered yeast |
AU2013201422B2 (en) | 2012-01-23 | 2015-04-09 | Ablynx Nv | Sequences directed against hepatocyte growth factor (HFG) and polypeptides comprising the same for the treatment of cancers and/or tumors |
UY34887A (en) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | OPTIMIZATION OF ANTIBODIES THAT FIX THE LYMPHOCYTE ACTIVATION GEN 3 (LAG-3) AND ITS USES |
CA2882684A1 (en) | 2012-08-21 | 2014-02-27 | Glaxo Group Limited | Compositions comprising a single variable domain and camostat mesylate (cm) |
WO2014043509A2 (en) * | 2012-09-13 | 2014-03-20 | Novartis Ag | Antigen binding molecule with terminal modifications |
CA2894834A1 (en) | 2012-12-11 | 2014-06-19 | Sekisui Specialty Chemicals America, Llc | Pvoh copolymers for personal care applications |
WO2014111550A1 (en) | 2013-01-17 | 2014-07-24 | Glaxosmithkline Intellectual Property Development Limited | Modified anti-serum albumin binding proteins |
UY35468A (en) | 2013-03-16 | 2014-10-31 | Novartis Ag | CANCER TREATMENT USING AN ANTI-CD19 CHEMERIC ANTIGEN RECEIVER |
AR097306A1 (en) | 2013-08-20 | 2016-03-02 | Merck Sharp & Dohme | MODULATION OF TUMOR IMMUNITY |
EP3178849B1 (en) | 2013-09-20 | 2019-03-20 | Bristol-Myers Squibb Company | Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors |
PL3049439T3 (en) | 2013-09-26 | 2020-07-13 | Ablynx N.V. | Bispecific nanobodies |
EP3757130A1 (en) | 2013-09-26 | 2020-12-30 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
RU2016122957A (en) | 2013-11-11 | 2017-12-19 | Армо Байосайенсиз, Инк. | Methods of using interleukin-10 for the treatment of diseases and disorders |
DK3081576T3 (en) | 2013-12-12 | 2019-10-21 | Shanghai hengrui pharmaceutical co ltd | PD-1 ANTIBODY, ANTI-BINDING FRAGMENT THEREOF AND MEDICAL USE THEREOF |
TWI681969B (en) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | Human antibodies to pd-1 |
JOP20200094A1 (en) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | Antibody molecules to pd-1 and uses thereof |
PT3116909T (en) | 2014-03-14 | 2020-01-30 | Novartis Ag | Antibody molecules to lag-3 and uses thereof |
EP3693386A1 (en) | 2014-05-16 | 2020-08-12 | Ablynx NV | Immunoglobulin variable domains |
TWI693232B (en) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | Covalently bonded diabodies having immunoreactivity with pd-1 and lag-3, and methods of use thereof |
HUE046556T2 (en) | 2014-07-08 | 2020-03-30 | Techno Umg Co Ltd | Thermoplastic resin composition and molded article thereof |
RS63364B1 (en) | 2014-08-11 | 2022-07-29 | Acerta Pharma Bv | Therapeutic combinations of a btk inhibitor, a pd-1 inhibitor and/or a pd-l1 inhibitor |
CN114099671A (en) | 2014-08-12 | 2022-03-01 | 鳄鱼生物科学公司 | Combination therapy with anti-CD 40 antibodies |
AP2017009765A0 (en) | 2014-08-19 | 2017-02-28 | Merck Sharp & Dohme | Anti-tigit antibodies |
SG10201912035YA (en) | 2015-04-17 | 2020-02-27 | Bristol Myers Squibb Co | Compositions comprising a combination of an anti-pd-1 antibody and another antibody |
JP2018523652A (en) | 2015-07-29 | 2018-08-23 | ノバルティス アーゲー | Combination of PD-1 antagonist and EGFR inhibitor |
CN108136003A (en) | 2015-07-29 | 2018-06-08 | 诺华股份有限公司 | The use in conjunction of anti-PD-1 and anti-M-CSF antibody in treatment of cancer |
MX2018001644A (en) | 2015-08-11 | 2018-11-09 | Wuxi Biologics Cayman Inc | Novel anti-pd-1 antibodies. |
BR112018003186A2 (en) | 2015-09-01 | 2018-09-25 | Agenus Inc. | anti-pd-1 antibodies and their methods of use |
AU2016332725A1 (en) | 2015-09-29 | 2018-03-22 | Celgene Corporation | PD-1 binding proteins and methods of use thereof |
MY192202A (en) | 2015-10-02 | 2022-08-06 | Hoffmann La Roche | Bispecific antibodies specific for pd1 and tim3 |
KR102072317B1 (en) | 2015-10-02 | 2020-01-31 | 에프. 호프만-라 로슈 아게 | Anti-PD1 Antibodies and Methods of Use |
UA125337C2 (en) | 2015-11-18 | 2022-02-23 | Мерк Шарп І Доум Корп. | Ctla4 binders |
BR112018010085A2 (en) | 2015-11-18 | 2018-11-13 | Merck Sharp & Dohme | pd1 / ctla4 binders |
SG11201804178YA (en) * | 2015-11-18 | 2018-06-28 | Merck Sharp & Dohme | Pd1 and/or lag3 binders |
KR20180081825A (en) | 2015-12-04 | 2018-07-17 | 베링거 인겔하임 인터내셔날 게엠베하 | Biparotopic polypeptides that antagonize WNT signaling in tumor cells |
UA125611C2 (en) | 2015-12-14 | 2022-05-04 | Макродженікс, Інк. | Bispecific molecules having immunoreactivity in relation to pd-1 and ctla-4, and methods of their use |
EP3389712B1 (en) | 2015-12-17 | 2024-04-10 | Novartis AG | Antibody molecules to pd-1 and uses thereof |
EP3243832A1 (en) | 2016-05-13 | 2017-11-15 | F. Hoffmann-La Roche AG | Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety |
EP3848393A1 (en) | 2016-05-18 | 2021-07-14 | Boehringer Ingelheim International GmbH | Antibody molecules for cancer treatment |
EP4101447A1 (en) | 2016-06-30 | 2022-12-14 | Nant Holdings IP, LLC | Nant cancer vaccine |
RU2656181C1 (en) | 2016-07-13 | 2018-05-31 | Закрытое Акционерное Общество "Биокад" | Anti-pd-1 antibodies, method for their production, and method of application |
MY189618A (en) | 2016-09-14 | 2022-02-21 | Beijing hanmi pharm co ltd | Antibody specifically binding to pd-1 and functional fragment thereof |
PE20191102A1 (en) | 2016-09-14 | 2019-08-23 | Abbvie Biotherapeutics Inc | ANTI-PD-1 ANTIBODIES AND THEIR USES |
WO2018053405A1 (en) | 2016-09-19 | 2018-03-22 | Celgene Corporation | Methods of treating immune disorders using pd-1 binding proteins |
CN116375876A (en) | 2017-04-05 | 2023-07-04 | 豪夫迈·罗氏有限公司 | Bispecific antibodies that specifically bind PD1 and LAG3 |
-
2016
- 2016-11-17 SG SG11201804178YA patent/SG11201804178YA/en unknown
- 2016-11-17 CA CA3132021A patent/CA3132021C/en active Active
- 2016-11-17 KR KR1020187016800A patent/KR102194188B1/en active IP Right Grant
- 2016-11-17 SG SG10201911035QA patent/SG10201911035QA/en unknown
- 2016-11-17 MX MX2018006245A patent/MX2018006245A/en unknown
- 2016-11-17 KR KR1020197028947A patent/KR102220275B1/en active IP Right Grant
- 2016-11-17 EA EA201891165A patent/EA201891165A1/en unknown
- 2016-11-17 CA CA3131983A patent/CA3131983C/en active Active
- 2016-11-17 BR BR112018010084A patent/BR112018010084A2/en active Search and Examination
- 2016-11-17 US US15/353,919 patent/US10323090B2/en active Active
- 2016-11-17 TN TNP/2018/000172A patent/TN2018000172A1/en unknown
- 2016-11-17 WO PCT/US2016/062394 patent/WO2017087589A2/en active Application Filing
- 2016-11-17 AU AU2016355570A patent/AU2016355570B2/en active Active
- 2016-11-17 JO JOP/2016/0244A patent/JO3744B1/en active
- 2016-11-17 MA MA043260A patent/MA43260A/en unknown
- 2016-11-17 UA UAA201806765A patent/UA121914C2/en unknown
- 2016-11-17 JP JP2018525608A patent/JP6817302B2/en active Active
- 2016-11-17 CR CR20180278A patent/CR20180278A/en unknown
- 2016-11-17 CA CA3004748A patent/CA3004748C/en active Active
- 2016-11-17 IL IL300122A patent/IL300122A/en unknown
- 2016-11-17 MY MYPI2018000773A patent/MY189018A/en unknown
- 2016-11-17 EP EP16805655.4A patent/EP3377531A2/en active Pending
- 2016-11-17 KR KR1020207036090A patent/KR102317574B1/en active IP Right Grant
- 2016-11-17 PE PE2018000983A patent/PE20181532A1/en unknown
- 2016-11-17 CN CN201680079323.1A patent/CN108473585B/en active Active
- 2016-11-17 TW TW111102788A patent/TW202216787A/en unknown
- 2016-11-17 TW TW105137705A patent/TWI754621B/en active
- 2016-11-17 GE GEAP201614812A patent/GEP20217220B/en unknown
- 2016-11-18 AR ARP160103543A patent/AR106754A1/en unknown
-
2018
- 2018-05-08 IL IL259224A patent/IL259224B2/en unknown
- 2018-05-15 CO CONC2018/0005126A patent/CO2018005126A2/en unknown
- 2018-05-15 NI NI201800061A patent/NI201800061A/en unknown
- 2018-05-15 SV SV2018005694A patent/SV2018005694A/en unknown
- 2018-05-17 CL CL2018001327A patent/CL2018001327A1/en unknown
- 2018-05-18 MX MX2023001356A patent/MX2023001356A/en unknown
- 2018-05-18 PH PH12018501080A patent/PH12018501080A1/en unknown
- 2018-05-18 DO DO2018000126A patent/DOP2018000126A/en unknown
- 2018-06-14 EC ECIEPI201845468A patent/ECSP18045468A/en unknown
- 2018-11-02 HK HK18114055.3A patent/HK1254951A1/en unknown
-
2019
- 2019-05-17 US US16/415,530 patent/US11155619B2/en active Active
- 2019-05-17 US US16/415,455 patent/US11168135B2/en active Active
- 2019-05-17 US US16/415,496 patent/US11168136B2/en active Active
- 2019-09-27 JP JP2019176483A patent/JP6845905B2/en active Active
-
2020
- 2020-03-27 AU AU2020202177A patent/AU2020202177B2/en active Active
- 2020-03-30 AU AU2020202238A patent/AU2020202238B2/en active Active
- 2020-09-29 CL CL2020002521A patent/CL2020002521A1/en unknown
- 2020-09-30 CL CL2020002531A patent/CL2020002531A1/en unknown
- 2020-12-17 JP JP2020209140A patent/JP7184866B2/en active Active
-
2021
- 2021-01-08 DO DO2021000005A patent/DOP2021000005A/en unknown
- 2021-10-08 US US17/497,597 patent/US20220041727A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201804178YA (en) | Pd1 and/or lag3 binders | |
SG11201804127SA (en) | Ctla4 binders | |
SG11201907753TA (en) | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof | |
SG11201804787UA (en) | Human immunodeficiency virus neutralizing antibodies | |
SG11201909081YA (en) | Anti-ilt4 antibodies and antigen-binding fragments | |
SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
SG11201811003PA (en) | Anti-pd-l1 antibodies and uses thereof | |
SG11201810883TA (en) | Combination therapy | |
SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
SG11201907580SA (en) | Combination therapies for treatment of bcma-related cancers and autoimmune disorders | |
SG11201807176XA (en) | TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF | |
SG11201903359RA (en) | Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma | |
SG11201906200WA (en) | Nucleic acid-polypeptide compositions and methods of inducing exon skipping | |
SG11201810600WA (en) | Fxr (nr1h4) modulating compounds | |
SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
SG11201803956UA (en) | Anti-dr5 antibodies and methods of use thereof | |
SG11201908787WA (en) | Novel bispecific antigen binding molecules capable of specific binding to cd40 and to fap | |
SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
SG11201908796XA (en) | Improved antigen binding receptors | |
SG11201805420SA (en) | Antibodies and conjugates thereof | |
SG11201910134SA (en) | Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
SG11201906341XA (en) | Improved serum albumin binders | |
SG11201806419RA (en) | Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates | |
SG11201407669QA (en) | Methods for improving safety of blood-brain barrier transport |